Regulation of aberrantly expressed SERPINH1 by antitumor miR-148a-5p inhibits cancer cell aggressiveness in gastric cancer.


Journal

Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 21 02 2020
accepted: 12 03 2020
revised: 12 03 2020
pubmed: 3 4 2020
medline: 18 11 2020
entrez: 3 4 2020
Statut: ppublish

Résumé

RNA-sequencing-based microRNA (miRNA) expression signatures have revealed that miR-148a-5p (the passenger strand of the miR-148a-duplex) is downregulated in various kinds of cancer tissues. Analysis of The Cancer Genome Atlas (TCGA) database showed that low expression of miR-148a-5p was predictive of a lower survival rate (p = 0.041) in patients with gastric cancer (GC). Downregulation of miR-148a-5p was confirmed in GC clinical specimens, and its ectopic expression attenuated GC cell proliferation. Our search for miRNA target genes identified a total of 18 oncogenic targets of miR-148a-5p in GC cells. Among these targets, high expression levels of six genes (THBS2, P4HA3, SERPINH1, CDH11, BCAT1, and KCNG3) were closely associated with a poor prognosis (10-year survival rates) in GC patients (p < 0.05) according to TCGA database analyses. Furthermore, we focused on SERPINH1 as a chaperone protein involved in collagen folding in humans. Aberrant expression of SERPINH1 (mRNA and protein levels) was confirmed in GC clinical specimens. Knockdown assays of SERPINH1 using siRNAs resulted in inhibition of the aggressive phenotype of GC cells. Exploring the molecular networks controlled by miRNAs (including miRNA passenger strands) will broaden our understanding of the molecular pathogenesis of GC.

Identifiants

pubmed: 32235846
doi: 10.1038/s10038-020-0746-6
pii: 10.1038/s10038-020-0746-6
doi:

Substances chimiques

Cadherins 0
HSP47 Heat-Shock Proteins 0
KCNG3 protein, human 0
MIRN148 microRNA, human 0
MicroRNAs 0
Potassium Channels, Voltage-Gated 0
RNA, Small Interfering 0
RNA-Induced Silencing Complex 0
SERPINH1 protein, human 0
Thrombospondins 0
thrombospondin 2 0
osteoblast cadherin 156621-71-5
P4HA3 protein, human EC 1.14.11.2
Procollagen-Proline Dioxygenase EC 1.14.11.2
BCAT1 protein, human EC 2.6.1.
Transaminases EC 2.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

647-656

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593 pmcid: 30207593
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49.
pubmed: 27664260 pmcid: 27664260
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.
pubmed: 27156933 pmcid: 27156933
Fontana E, Smyth EC. Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol. 2016;8:113–25.
pubmed: 26929787 pmcid: 26929787
Pellino A, Riello E, Nappo F, Brignola S, Murgioni S, Djaballah SA, et al. Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives. World J Gastroenterol. 2019;25:5773–88.
pubmed: 31636471 pmcid: 31636471
Verma R, Sharma PC. Next generation sequencing-based emerging trends in molecular biology of gastric cancer. Am J Cancer Res. 2018;8:207–25.
pubmed: 29511593 pmcid: 29511593
Hudler P. Challenges of deciphering gastric cancer heterogeneity. World J Gastroenterol. 2015;21:10510–27.
pubmed: 26457012 pmcid: 26457012
Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs—an update. Nat Rev Clin Oncol. 2018;15:541–63.
pubmed: 29784926 pmcid: 29784926
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.
pubmed: 25027649 pmcid: 25027649
Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21–37.
pubmed: 30108335 pmcid: 30108335
Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.
pubmed: 25998712 pmcid: 25998712
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.
pubmed: 28209991 pmcid: 28209991
Koshizuka K, Nohata N, Hanazawa T, Kikkawa N, Arai T, Okato A, et al. Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs. Oncotarget. 2017;8:30288–304.
pubmed: 28415821 pmcid: 28415821
Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, et al. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer. 2017;117:409–20.
pubmed: 28641312 pmcid: 28641312
Yonemori K, Seki N, Idichi T, Kurahara H, Osako Y, Koshizuka K, et al. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Oncotarget. 2017;8:70097–115.
pubmed: 29050264 pmcid: 29050264
Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, et al. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. J Hum Genet. 2018;63:1197–210.
pubmed: 30228364 pmcid: 30228364
Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, et al. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. 2019;14:426–46.
pubmed: 31755218 pmcid: 31755218
Osako Y, Seki N, Koshizuka K, Okato A, Idichi T, Arai T, et al. Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer cell migration and invasion in esophageal squamous cell carcinoma. J Hum Genet. 2017;62:935–44.
pubmed: 28659612
Sugawara S, Yamada Y, Arai T, Okato A, Idichi T, Kato M, et al. Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis. J Hum Genet. 2018;63:657–68.
pubmed: 29540855 pmcid: 29540855
Misono S, Seki N, Mizuno K, Yamada Y, Uchida A, Arai T, et al. Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. J Hum Genet. 2018;63:1015–28.
pubmed: 30082847 pmcid: 30082847
Fukuhisa H, Seki N, Idichi T, Kurahara H, Yamada Y, Toda H, et al. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. J Hum Genet. 2019;64:521–34.
pubmed: 30858505 pmcid: 30858505
Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554–65.
pubmed: 23684942 pmcid: 23684942
Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, Xavier RJ. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood. 2010;115:5376–84.
pubmed: 20410506 pmcid: 20410506
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009;5:e1000676.
pubmed: 19798449 pmcid: 19798449
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.
pubmed: 25894828 pmcid: 25894828
Arienti C, Pignatta S, Tesei A. Epidermal growth factor receptor family and its role in gastric cancer. Front Oncol. 2019;9:1308.
pubmed: 31850207 pmcid: 31850207
Selim JH, Shaheen S, Sheu WC, Hsueh CT. Targeted and novel therapy in advanced gastric cancer. Exp Hematol Oncol. 2019;8:25.
pubmed: 31632839 pmcid: 31632839
Alessandrini L, Manchi M, De Re V, Dolcetti R, Canzonieri V. Proposed molecular and miRNA classification of gastric cancer. Int J Mol Sci. 2018;19:E1683.
Necula L, Matei L, Dragu D, Neagu AI, Mambet C, Nedeianu S, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25:2029–44.
pubmed: 31114131 pmcid: 31114131
Komatsu S, Otsuji E. Essential updates 2017/2018: recent topics in the treatment and research of gastric cancer in Japan. Ann Gastroenterol Surg. 2019;3:581–91.
pubmed: 31788646 pmcid: 31788646
Stojanovic J, Tognetto A, Tiziano DF, Leoncini E, Posteraro B, Pastorino R, et al. MicroRNA expression profiles as diagnostic biomarkers of gastric cancer: a systematic literature review. Biomarkers. 2019;24:110–9.
pubmed: 30387681 pmcid: 30387681
Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, et al. Molecular pathogenesis of pancreatic ductal adenocarcinoma: impact of passenger strand of pre-miR-148a on gene regulation. Cancer Sci. 2018;109:2013–26.
pubmed: 29660218 pmcid: 29660218
Duan F, Liu W, Fu X, Feng Y, Dai L, Cui S, et al. Evaluating the prognostic value of miR-148/152 family in cancers: based on a systemic review of observational studies. Oncotarget. 2017;8:77999–8010.
pubmed: 29100442 pmcid: 29100442
Li Y, Deng X, Zeng X, Peng X. The role of mir-148a in cancer. J Cancer. 2016;7:1233–41.
pubmed: 27390598 pmcid: 27390598
Xia J, Guo X, Yan J, Deng K. The role of miR-148a in gastric cancer. J Cancer Res Clin Oncol. 2014;140:1451–6.
pubmed: 24659367 pmcid: 24659367
Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players. Mol Cancer. 2013;12:43.
pubmed: 23683438 pmcid: 23683438
Nakamura Y, Tanaka F, Nagahara H, Ieta K, Haraguchi N, Mimori K, et al. Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol. 2007;14:885–92.
pubmed: 17151793
Chun HK, Chung KS, Kim HC, Kang JE, Kang MA, Kim JT, et al. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep. 2010;43:349–54.
pubmed: 20510019
Kim TW, Lee SJ, Park YJ, Park SY, Oh BM, Park YS, et al. Opa-interacting protein 5 modulates docetaxel-induced cell death via regulation of mitophagy in gastric cancer. Tumour Biol. 2017;39:1010428317733985.
pubmed: 29034772 pmcid: 29034772
Xu Y, Yu W, Yang T, Zhang M, Liang C, Cai X, et al. Overexpression of BCAT1 is a prognostic marker in gastric cancer. Hum Pathol. 2018;75:41–6.
pubmed: 29447920 pmcid: 29447920
Duarte BDP, Bonatto D. The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research. J Cancer Res Clin Oncol. 2018;144:2319–28.
pubmed: 30128672 pmcid: 30128672
Ito S, Nagata K. Biology of Hsp47 (Serpin H1), a collagen-specific molecular chaperone. Semin Cell Dev Biol. 2017;62:142–51.
pubmed: 27838364 pmcid: 27838364
Kamikawaji K, Seki N, Watanabe M, Mataki H, Kumamoto T, Takagi K, et al. Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis. J Hum Genet. 2016;61:985–93.
pubmed: 27488440 pmcid: 27488440
Yamada Y, Sugawara S, Arai T, Kojima S, Kato M, Okato A, et al. Molecular pathogenesis of renal cell carcinoma: impact of the anti-tumor miR-29 family on gene regulation. Int J Urol. 2018;25:953–65.
pubmed: 30153702 pmcid: 30153702
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014;35:497–506.
pubmed: 24130168 pmcid: 24130168

Auteurs

Kosuke Kawagoe (K)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Masumi Wada (M)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Tetsuya Idichi (T)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Reona Okada (R)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.

Yasutaka Yamada (Y)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.

Shogo Moriya (S)

Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba, Japan.

Keishi Okubo (K)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.

Daisuke Matsushita (D)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Takaaki Arigami (T)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Hiroshi Kurahara (H)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Kosei Maemura (K)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Shoji Natsugoe (S)

Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Naohiko Seki (N)

Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan. naoseki@faculty.chiba-u.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH